The anti-GD2 therapy naxitamab has been included in the NCCN Clinical Practice Guidelines in Oncology for the treatment of ...

Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of ...

The National Comprehensive Cancer Network (NCCN) policy summit highlighted the need for improved communication between ...